Determination of Regulatory Review Period for Purposes of Patent Extension; NIKTIMVO
Updated 6 hours ago ()
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for NIKTIMVO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.
- Tags
- information blocking, Notice, Health and Human Services Department, Food and Drug Administration
- Related exam domains
- None matched
- Source record id
- 2025-18809
- First seen by InfoSec Signals
- Sep 23, 2026
Source: Federal Register API, Office of the Federal Register, National Archives and Records Administration about this source more from it
Exam domain labels come from a keyword heuristic and are study hints, not an official mapping. The summary is the publisher's own text, shortened; the linked record is authoritative.